These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23155225)

  • 1. Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC.
    Evans T
    Anticancer Res; 2012 Nov; 32(11):4629-38. PubMed ID: 23155225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
    Gadgeel SM
    Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of antiangiogenic therapy in non-small cell lung cancer.
    Giaccone G
    Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
    Gridelli C; Maione P; Rossi A; De Marinis F
    Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging antiangiogenic therapies for non-small-cell lung cancer.
    Blakely C; Jahan T
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumor neovasculature in non-small-cell lung cancer.
    Pallis AG; Syrigos KN
    Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
    Socinski MA
    Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy in nonsmall cell lung cancer.
    Gutierrez M; Giaccone G
    Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond bevacizumab: antiangiogenic agents.
    Rogosin S; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.
    Gori B; Ricciardi S; Fulvi A; Del Signore E; de Marinis F
    Future Oncol; 2012 May; 8(5):559-73. PubMed ID: 22646771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Subramanian J; Morgensztern D; Govindan R
    Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiangiogenic agents: current limits in thoracic oncology].
    Dansin E; Lauridant G; Chahine B
    Bull Cancer; 2012 Nov; 99(11):1083-91. PubMed ID: 23113985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.
    Wozniak A
    Crit Rev Oncol Hematol; 2012 May; 82(2):200-12. PubMed ID: 21715183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab in non-small-cell lung cancer: a review.
    Planchard D
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Ramalingam S; Belani CP
    Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.